Elutia Inc. (ELUT)
NASDAQ: ELUT · Real-Time Price · USD
0.8951
-0.0471 (-5.00%)
At close: Nov 7, 2025, 4:00 PM EST
0.8701
-0.0250 (-2.79%)
After-hours: Nov 7, 2025, 4:35 PM EST
Elutia Revenue
Elutia had revenue of $3.32M in the quarter ending September 30, 2025, a decrease of -43.89%. This brings the company's revenue in the last twelve months to $21.75M, down -12.25% year-over-year. In the year 2024, Elutia had annual revenue of $24.38M, down -1.50%.
Revenue (ttm)
$21.75M
Revenue Growth
-12.25%
P/S Ratio
1.62
Revenue / Employee
$426,392
Employees
51
Market Cap
37.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24.38M | -370.00K | -1.50% |
| Dec 31, 2023 | 24.75M | 896.00K | 3.76% |
| Dec 31, 2022 | 23.85M | -23.54M | -49.68% |
| Dec 31, 2021 | 47.39M | 4.71M | 11.03% |
| Dec 31, 2020 | 42.68M | -219.00K | -0.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ELUT News
- 2 days ago - Elutia Inc. (ELUT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development - GlobeNewsWire
- 16 days ago - Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - GlobeNewsWire
- 25 days ago - Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21 - GlobeNewsWire
- 4 weeks ago - Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors - GlobeNewsWire
- 5 weeks ago - Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - GlobeNewsWire
- 7 weeks ago - Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation - GlobeNewsWire
- 2 months ago - Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million - GlobeNewsWire